We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to cre... Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss. Show more
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing...
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -6.55 | -13.9391359864 | 46.99 | 52.22 | 35.67 | 58231 | 44.55453444 | CS |
4 | 4.85 | 13.6274234335 | 35.59 | 55.06 | 30.005 | 86357 | 39.75633189 | CS |
12 | -14.58 | -26.4994547437 | 55.02 | 97.91 | 30.005 | 62361 | 46.61518887 | CS |
26 | 27.44 | 211.076923077 | 13 | 97.91 | 13 | 56013 | 46.93158631 | CS |
52 | 27.44 | 211.076923077 | 13 | 97.91 | 13 | 56013 | 46.93158631 | CS |
156 | 27.44 | 211.076923077 | 13 | 97.91 | 13 | 56013 | 46.93158631 | CS |
260 | 0 | 0 | 0 | 44.1695 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions